“So we have good visibility to the first half. It's when those – most of those orders will ship. We would expect that the Analytical Instruments business will be a really nice contributor to our growth for the year.”

In context

“tion throughout the early phase of the pandemic, making sure we have robust pipelines. You saw that in the stream of launches in our chromatography, mass spectrometry and electron microscopy businesses, those products have been well adopted. We're clearly growing very well. And as you know, we've also built out a very strong presence in enabling the next generation of semiconductors, battery applications. The most advanced aspects of material science is a different market position than really anybody else has in the industry and that's driving great growth, right? And you can see it in our electron microscopy numbers. I'm very proud of how the team has executed. So, that's kind of the context of why the elevated growth. So as I think about bookings demand, very strong throughout the year. So we have good visibility to the first half. It's when those – most of those orders will ship. We would expect that the Analytical Instruments business will be a really nice contributor to our growth for the year. And I think it's reasonable to assume that the growth normalizes more in the second half as an assumption. It's not that I see something different or something happening in the market conditions, but our visibility is typically six months. So at the end of the first quarter, we'll have good visibility into the third quarter, and we'll keep you posted. But I think for modeling purpose, I think, normalization in the second half is a good assumption. Patrick Donnelly: Okay, that's helpful. And then maybe one for Stephen on the margins. Gross margins seem to have rebased. I would love just your perspective of what those look like in 2023, first off. And then maybe just the additional areas of leverage kind of down the P&L coming out of COVID, you mentioned maybe some elevated strategic invest”